Quartette (levonorgestrel [LNG]/ethinyl estradiol [EE] and EE) is an ascending-dose, extended-regimen combined oral contraceptive (COC) that consists of a constant dose of LNG 150 µg on days 1 to 84 with EE 20 µg on days 1 to 42, 25 µg on days 43 to 63, 30 µg on days 64 to 84, and 10 µg of EE monotherapy on days 85 to 91. A population pharmacokinetic (PK) model for EE was developed using nonlinear mixed-effects modeling to characterize the PK profile of EE administered in Quartette and other extended-regimen LNG/EE COCs. Model-predicted plasma concentration–time profiles demonstrated a stepwise increase in systemic exposure to EE during the first 84 days of the cycle following each EE dose change. Lower concentrations of EE were noted during the final 7-day period of EE 10 µg. Gradual increases in EE seen with Quartette may decrease the incidence of unscheduled bleeding frequently observed during early cycles of extended-regimen COCs.
KrishnanSKileyJ. The lowest-dose, extended-cycle combined oral contraceptive pill with continuous ethinyl estradiol in the United States: a review of the literature on ethinyl estradiol 20 mug/levonorgestrel 100 mug + ethinyl estradiol 10 mug. Int J Womens Health. 2010;2:235–239.
2.
AndersonFDHaitH. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception. 2003;68(2):89–96.
3.
WiegratzIStahlbergSMantheyT. Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy. Contraception. 2011;84(2):133–143.
4.
AndersonFDGibbonsWPortmanD. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception. 2006;73(3):229–234.
5.
KrollRReapeKZMargolisM. The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol. Contraception. 2010;81(1):41–48.
6.
KaunitzAMPortmanDJHaitHReapeKZ. Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive. Contraception. 2009;79(5):350–355.
7.
PortmanDJHowardBWeissHKaunitzAMRicciottiN. Multicenter open-label study to evaluate efficacy and safety of an ascending-dose, extended-regimen ethinyl estradiol/levonorgestrel combination oral contraceptive for preventing pregnancy in women [abstract]. Fertil Steril. 2012;98:S196–S197.
8.
ReapeKZDiLibertiCEHendyCHVolpeEJ. Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive. Contraception. 2008;77(1):34–39.
9.
CarrBGerstenJHowardBWeissH. Bleeding patterns with three ascending-dose, extended-cycle oral contraceptives (OCs) vs Seasonale®. Presented at: 61st Annual Clinical Meeting of the American College of Obstetricians and Gynecologists; May 4-8, 2013; New Orleans, LA.
10.
HumpelMNieuweboerBWendtHSpeckU. Investigations of pharmacokinetics of ethinyloestradiol to specific consideration of a possible first-pass effect in women. Contraception. 1979;19(4):421–432.
11.
StanczykFZMroszczakEJLingT. Plasma levels and pharmacokinetics of norethindrone and ethinylestradiol administered in solution and as tablets to women. Contraception. 1983;28(3):241–251.
12.
BergstrandMHookerACWallinJEKarlssonMO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–151.
13.
DarwishMBondMRicciottiNHsiehJFiedler-KellyJGraselaT. Pharmacokinetic profile of an ascending-dose, estrogen/progestin combination oral contraceptive [abstract]. Reprod Sci. 2013;20(3 suppl):193A.
14.
WesthoffCLTorgalAHMayedaERPikeMCStanczykFZ. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception. 2010;81(6):474–480.
15.
ReifSSnelderNBlodeH. Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study. J Fam Plann Reprod Health Care. 2013;39(2):e1.
16.
KanarkowskiRTornatoreKMD'AmbrosioRGardnerMJJuskoWJ. Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. Clin Pharmacol Ther. 1988;43(1):23–31.
17.
GerstmanBBPiperJMTomitaDKFergusonWJStadelBVLundinFE. Oral contraceptives estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol. 1991;133(1):32–37.
18.
van Hylckama VliegAHelmerhorstFMVandenbrouckeJPDoggenCJRosendaalFR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009;339:b2921.
19.
HickeyMAgarwalS. Unscheduled bleeding in combined oral contraceptive users: focus on extended-cycle and continuous-use regimens. J Fam Plann Reprod Health Care. 2009;35(4):245–248.
20.
BrownTJScherzBHochbergRBMacLuskyNJ. Regulation of estrogen receptor concentrations in the rat brain: effects of sustained androgen and estrogen exposure. Neuroendocrinology. 1996;63(1):53–60.
21.
KlingeCMRaoV. The steroid hormone receptors. In: HiscockT., eds. Gynecology & Obstetrics. Volume 5: Reproductive endocrinology, infertility, and genetics. http://www.glowm.com/resources/glowm/cd/pages/v5/v5c004.html. Accessed November 27, 2012.
22.
EndrikatJGerlingerCPlettigK. A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual bleeding during low-dose oral contraceptive use. Gynecol Endocrinol. 2003;17(2):107–114.
